Investigational drug · Phase 2
paxalisib
Also called: SVG103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "paxalisib"
First trial start
2026
Jul 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "paxalisib", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Focal Cortical Dysplasia
- Tuberous Sclerosis Complex (TSC)
- Hemimegalencephaly
Largest trials
Live from ClinicalTrials.gov: studies naming "paxalisib" as an intervention, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- Combination Therapy for the Treatment of Diffuse Midline GliomasPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05009992 · 360 participants (planned) · Start Oct 20, 2021 · Primary completion Dec 31, 2027
Drug: ONC201; Paxalisib and 1 more · For: Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent Diffuse Intrinsic Pontine Glioma and 3 more
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 32 sites in all
Australian & New Zealand Children's Haematology/Oncology GroupAcademic, hospital or other
NCT06208657 · 90 participants (planned) · Start Jul 10, 2024 · Primary completion Dec 2030
Drug: Paxalisib; Opdualag and 2 more · For: Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor and 2 more
Sites: Newcastle, Australia; Sydney, Australia; Brisbane, Australia · 14 sites in all
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT07391215 · 64 participants (planned) · Start Jan 19, 2026 · Primary completion Jan 19, 2029
Drug: Paxalisib; Temozolomide capsule · For: Malignant Primary Gliomas; Glioblastoma Multiforme (GBM)
Sites: Sutton, United Kingdom
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT03994796 · 50 participants · Start Oct 17, 2019 · Primary completion Nov 13, 2025
Drug: Abemaciclib; PI3K Inhibitor paxalisib and 2 more · For: CDK Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm and 4 more
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 435 sites in all
- Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaCompleted
Kazia Therapeutics LimitedIndustry
NCT03522298 · 30 participants · Start May 15, 2018 · Primary completion Mar 30, 2023
Drug: Paxalisib (GDC-0084) · For: Glioblastoma, Adult
Sites: Los Angeles, California; Aurora, Colorado; Boston, Massachusetts · 6 sites in all
Sabine Mueller, MD, PhDAcademic, hospital or other
NCT07447076 · 29 participants (planned) · Start Jun 17, 2026 · Primary completion Dec 31, 2035
Drug: Gemcitabine; Paxalisib · For: Recurrent Atypical Teratoid/Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Sites: San Francisco, California; Baltimore, Maryland; Seattle, Washington · 4 sites in all
Lakshmi Nayak, MDAcademic, hospital or other
NCT04906096 · 25 participants (planned) · Start Jun 1, 2021 · Primary completion Dec 1, 2026
Drug: PAXALISIB · For: Primary Central Nervous System Lymphoma; Non-Hodgkin Lymphoma of Extranodal Site
Sites: Boston, Massachusetts · 2 sites in all
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT05183204 · 24 participants · Start Feb 14, 2022 · Primary completion Aug 10, 2026
Drug: Paxalisib; Metformin · For: Glioblastoma
Sites: New York, New York
SovargenIndustry
NCT07287202 · 12 participants (planned) · Start Jul 14, 2026 · Primary completion Feb 2027
Drug: SVG103 · For: Focal Cortical Dysplasia; Tuberous Sclerosis Complex (TSC); Hemimegalencephaly
Sites: Heidelberg, Australia; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses.
Segui E, Gomez Tejeda Zañudo J, Graham N, et al. · Cancer Res Commun 2026
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.
Garcia DM, Lin WH, Wickland DP, et al. · Neuro Oncol 2026
- Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.
Juanes-Gusano D, Fernández-Roldán B, Coveñas R, et al. · Int J Mol Sci 2026
- MYCN drives pediatric glioma transformation from neural progenitors and creates distinct therapeutic vulnerabilities.
Gatesman TA, Varadharajan S, Johnson BJ, et al. · Cell Rep 2026
- Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.
Lim JH, Mun SJ, Kang HM, et al. · Signal Transduct Target Ther 2026
- Activation of chaperone-mediated autophagy suppresses glioblastoma by promoting wild-type IDH1/isocitrate dehydrogenase 1 degradation.
Tang W, Chen B, Ho PW, et al. · Autophagy 2026
Also in development for Focal Cortical Dysplasia
- RadiprodilPhase 32 trials
GRIN Therapeutics, Inc. · GRIN-related Neurodevelopmental Disorder, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.